Carmen D. Schweighofer

1.3k total citations
24 papers, 967 citations indexed

About

Carmen D. Schweighofer is a scholar working on Genetics, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Carmen D. Schweighofer has authored 24 papers receiving a total of 967 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Genetics, 17 papers in Immunology and 16 papers in Pathology and Forensic Medicine. Recurrent topics in Carmen D. Schweighofer's work include Chronic Lymphocytic Leukemia Research (24 papers), Immunodeficiency and Autoimmune Disorders (17 papers) and Lymphoma Diagnosis and Treatment (16 papers). Carmen D. Schweighofer is often cited by papers focused on Chronic Lymphocytic Leukemia Research (24 papers), Immunodeficiency and Autoimmune Disorders (17 papers) and Lymphoma Diagnosis and Treatment (16 papers). Carmen D. Schweighofer collaborates with scholars based in Germany, United States and France. Carmen D. Schweighofer's co-authors include Michael Hallek, Clemens‐Martin Wendtner, Barbara Eichhorst, Raymonde Busch, Kirsten Fischer, Stephan Stilgenbauer, Michael Kneba, Hartmut Döhner, Matthias Ritgen and Valentin Goede and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Carmen D. Schweighofer

24 papers receiving 942 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carmen D. Schweighofer Germany	15	840	747	394	201	123	24	967
Paul Moreton United Kingdom	12	712 0.8×	649 0.9×	425 1.1×	160 0.8×	74 0.6×	21	872
Alice Lynn United States	5	932 1.1×	674 0.9×	390 1.0×	281 1.4×	87 0.7×	8	990
Małgorzata Wach Poland	11	573 0.7×	448 0.6×	199 0.5×	221 1.1×	84 0.7×	35	695
Anna‐Maria Fink Germany	17	886 1.1×	818 1.1×	364 0.9×	204 1.0×	159 1.3×	58	1.0k
Myriam Mendila Germany	9	778 0.9×	752 1.0×	390 1.0×	163 0.8×	109 0.9×	16	947
Sandra Kanan United States	11	537 0.6×	474 0.6×	292 0.7×	171 0.9×	74 0.6×	23	765
Andreas Agathangelidis Greece	17	645 0.8×	481 0.6×	440 1.1×	98 0.5×	40 0.3×	67	819
James D’Rozario Australia	10	565 0.7×	399 0.5×	212 0.5×	259 1.3×	109 0.9×	25	872
Matthew Kaufman United States	8	565 0.7×	368 0.5×	346 0.9×	98 0.5×	42 0.3×	26	723
K Pesek United States	8	393 0.5×	495 0.7×	166 0.4×	264 1.3×	50 0.4×	8	711

Countries citing papers authored by Carmen D. Schweighofer

Since Specialization

Citations

This map shows the geographic impact of Carmen D. Schweighofer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carmen D. Schweighofer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carmen D. Schweighofer more than expected).

Fields of papers citing papers by Carmen D. Schweighofer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carmen D. Schweighofer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carmen D. Schweighofer. The network helps show where Carmen D. Schweighofer may publish in the future.

Co-authorship network of co-authors of Carmen D. Schweighofer

This figure shows the co-authorship network connecting the top 25 collaborators of Carmen D. Schweighofer. A scholar is included among the top collaborators of Carmen D. Schweighofer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carmen D. Schweighofer. Carmen D. Schweighofer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schweighofer, Carmen D., Florence Cymbalista, Carolin Müller, et al.. (2013). Early Versus Deferred Treatment With Combined Fludarabine, Cyclophosphamide and Rituximab (FCR) Improves Event-Free Survival In Patients With High-Risk Binet Stage A Chronic Lymphocytic Leukemia – First Results Of a Randomized German-French Cooperative Phase III Trial. Blood. 122(21). 524–524. 30 indexed citations

Schweighofer, Carmen D., Armin Tuchscherer, Benno Rattel, et al.. (2012). Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study. Cancer Immunology Immunotherapy. 61(12). 2367–2373. 7 indexed citations

Schweighofer, Carmen D., Kevin R. Coombes, Tadeusz Majewski, et al.. (2012). Genomic Variation by Whole-Genome SNP Mapping Arrays Predicts Time-to-Event Outcome in Patients with Chronic Lymphocytic Leukemia. Journal of Molecular Diagnostics. 15(2). 196–209. 19 indexed citations

Duzkale, Hatice, Carmen D. Schweighofer, Kevin R. Coombes, et al.. (2011). LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients. Blood. 117(15). 4076–4084. 26 indexed citations

Duzkale, Hatice, Carmen D. Schweighofer, Kevin R. Coombes, et al.. (2011). *104 LDOC1 mRNA Is Differentially Expressed in Chronic Lymphocytic Leukemia and Predicts Overall Survival in Untreated Patients. Clinical Lymphoma Myeloma & Leukemia. 11. S120–S121. 1 indexed citations

Huh, Yang O., Carmen D. Schweighofer, Rhett P. Ketterling, et al.. (2011). Chronic Lymphocytic Leukemia With t(14;19)(q32;q13) Is Characterized by Atypical Morphologic and Immunophenotypic Features and Distinctive Genetic Features. American Journal of Clinical Pathology. 135(5). 686–696. 25 indexed citations

Schweighofer, Carmen D., Yang O. Huh, Rajyalakshmi Luthra, et al.. (2010). The B cell antigen receptor in atypical chronic lymphocytic leukemia with t(14;19)(q32;q13) demonstrates remarkable stereotypy. International Journal of Cancer. 128(11). 2759–2764. 14 indexed citations

Schweighofer, Carmen D.. (2010). First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab. OncoTargets and Therapy. 3. 53–53. 14 indexed citations

Eichhorst, Barbara, Raymonde Busch, Stephan Stilgenbauer, et al.. (2009). First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood. 114(16). 3382–3391. 238 indexed citations

10.

Fischer, Kirsten, Stephan Stilgenbauer, Carmen D. Schweighofer, et al.. (2008). Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG). Blood. 112(11). 330–330. 71 indexed citations

11.

Schweighofer, Carmen D., Matthias Ritgen, Barbara Eichhorst, et al.. (2008). Consolidation with alemtuzumab improves progression‐free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission – long‐term follow‐up of a randomized phase III trial of the German CLL Study Group (GCLLSG). British Journal of Haematology. 144(1). 95–98. 76 indexed citations

12.

Schweighofer, Carmen D., Michael Hallek, & Clemens‐Martin Wendtner. (2008). Eradication of minimal residual disease in chronic lymphocytic leukemia. Current Hematologic Malignancy Reports. 3(1). 54–60. 2 indexed citations

13.

Schweighofer, Carmen D., Gerd Fätkenheuer, Peter Staib, Michael Hallek, & Marcel Reiser. (2007). Lyme Disease in a Patient with Chronic Lymphocytic Leukemia Mimics Leukemic Meningeosis. Oncology Research and Treatment. 30(11). 564–566. 4 indexed citations

14.

Eichhorst, Barbara, Raymonde Busch, Martina Stauch, et al.. (2007). No Significant Clinical Benefit of First Line Therapy with Fludarabine (F) in Comparison to Chlorambucil (Clb) in Elderly Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Phase III Study of the German CLL Study Group (GCLLSG).. Blood. 110(11). 629–629. 21 indexed citations

15.

Fischer, Kirsten, Stephan Stilgenbauer, Carmen D. Schweighofer, et al.. (2007). Bendamustine in Combination with Rituximab (BR) for Patients with Relapsed Chronic Lymphocytic Leukemia (CLL): A Multicentre Phase II Trial of the German CLL Study Group (GCLLSG).. Blood. 110(11). 3106–3106. 15 indexed citations

16.

Fischer, Kirsten, Carmen D. Schweighofer, Matthias Ritgen, et al.. (2007). Dose Escalation Study To Evaluate Dose Limiting Toxicity (DLT), Maximum Tolerated Dose (MTD) and Safety of Alemtuzumab for Consolidation Therapy in Patients with Chronic Lymphoycytic Leukemia: Phase I/II Trial of the German CLL Study Group (GCLLSG).. Blood. 110(11). 2053–2053. 7 indexed citations

17.

Eichhorst, Barbara, Raymonde Busch, Carmen D. Schweighofer, et al.. (2006). Due to low infection rates no routine anti‐infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine‐based first line therapy. British Journal of Haematology. 136(1). 63–72. 21 indexed citations

18.

Gianni, Alessandro M., Carmelo Carlo‐Stella, Anna Guidetti, et al.. (2006). Two Phase I Open-Label Studies of the Fully Human HLA-DR-Specific IgG4 Monoclonal Antibody 1D09C3 in Patients with Relapsed and/or Refractory B-Cell Lymphoproliferative Neoplasias on a Weekly and Bi-Weekly Dosing Scheme.. Blood. 108(11). 2730–2730. 1 indexed citations

19.

Ritgen, Matthias, Carmen D. Schweighofer, Barbara Eichhorst, et al.. (2004). Consolidation with Alemtuzumab in First Remission Induces Pronounced MRD Reduction and Clinical Remissions - Update on a Randomized Phase III Trial of the German CLL Study Group (GCLLSG).. Blood. 104(11). 2506–2506. 5 indexed citations

20.

Wendtner, Clemens‐Martin, David M. Kofler, Hans Theiß, et al.. (2002). Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. Blood. 100(5). 1655–1661. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact